Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

Active:	Yes
Cancer Type:	Unknown Primary	NCT ID:	NCT03435796
Trial Phases:	Phase II Phase III	Protocol IDs:	GC-LTFU-001 (primary) NCI-2018-00957 U1111-1206-8250 2017-001465-24
Eligibility:	0 Years and older, Male and Female	Study Type:	Other
Study Sponsor:	Celgene
NCI Full Details:	http://clinicaltrials.gov/show/NCT03435796

Summary

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all
pediatric and adult participants exposed to Gene-modified (GM) T cell therapy participating
in a previous Celgene sponsored or Celgene alliance partner sponsored study.

Participants who received at least one GM T cell infusion will be asked to enroll in this
LTFU protocol upon either premature discontinuation from, or completion of the prior parent
treatment protocol.

Objectives

Subjects participating in this study will be followed from time of roll-over from the parent
GM T protocol until 15 years after the last GMT infusion, withdrawal of consent, lost to
follow-up, or death, whichever occurs first. Both local and central laboratory evaluations
and safety assessments will be conducted during this trial. In addition, pediatric subjects
will be monitored for growth, development and sexual maturity.

Stage 5 per Tanner Staging Criteria must be reached prior to study discontinuation.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.